[go: up one dir, main page]

AR031356A1 - Compuesto lacta mico - Google Patents

Compuesto lacta mico

Info

Publication number
AR031356A1
AR031356A1 ARP010105339A ARP010105339A AR031356A1 AR 031356 A1 AR031356 A1 AR 031356A1 AR P010105339 A ARP010105339 A AR P010105339A AR P010105339 A ARP010105339 A AR P010105339A AR 031356 A1 AR031356 A1 AR 031356A1
Authority
AR
Argentina
Prior art keywords
lacta
mico
compound
procedures
methyl
Prior art date
Application number
ARP010105339A
Other languages
English (en)
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of AR031356A1 publication Critical patent/AR031356A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D223/00Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16Benzazepines; Hydrogenated benzazepines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Cephalosporin Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyrrole Compounds (AREA)

Abstract

Dihidrato cristalino de (N)-((S)-2-hidroxi-3-metil-butiril)-1-(L-alaninil)-(S)-1-amino-3-metil-4,5,6,7-tetrahidro-2H-3-benzoazepin-2-ona, composiciones del mismo y procedimientos para utilizar el mismo, procedimientos para prepararlo y procedimientos para preparar sus intermediarios.
ARP010105339A 2000-11-17 2001-11-15 Compuesto lacta mico AR031356A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US24965600P 2000-11-17 2000-11-17

Publications (1)

Publication Number Publication Date
AR031356A1 true AR031356A1 (es) 2003-09-17

Family

ID=22944436

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010105339A AR031356A1 (es) 2000-11-17 2001-11-15 Compuesto lacta mico

Country Status (33)

Country Link
US (1) US20040248878A1 (es)
EP (1) EP1353910B1 (es)
JP (1) JP4116431B2 (es)
KR (1) KR20030045194A (es)
CN (2) CN100516047C (es)
AR (1) AR031356A1 (es)
AT (1) ATE362919T1 (es)
AU (2) AU2002224321B2 (es)
BR (1) BR0115424A (es)
CA (1) CA2425497C (es)
CY (1) CY1106682T1 (es)
CZ (1) CZ20031340A3 (es)
DE (1) DE60128587T2 (es)
DK (1) DK1353910T3 (es)
DZ (1) DZ3454A1 (es)
EA (1) EA006919B1 (es)
EC (1) ECSP034598A (es)
ES (1) ES2286162T3 (es)
HR (1) HRP20030385A2 (es)
HU (1) HUP0301862A3 (es)
IL (1) IL155275A0 (es)
MX (1) MXPA03004250A (es)
MY (1) MY141607A (es)
NO (1) NO325217B1 (es)
PE (1) PE20020798A1 (es)
PL (1) PL211018B1 (es)
PT (1) PT1353910E (es)
SK (1) SK287794B6 (es)
SV (1) SV2003000741A (es)
TW (1) TWI235151B (es)
UA (1) UA77165C2 (es)
WO (1) WO2002040451A2 (es)
ZA (1) ZA200303411B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA74849C2 (en) * 2000-11-17 2006-02-15 Lilly Co Eli Lactam
MXPA05006567A (es) 2002-12-20 2005-08-16 Glaxo Group Ltd Derivados de benzazepina para el tratamiento de trastornos neurologicos.
CN102558155A (zh) 2003-01-14 2012-07-11 阿伦纳药品公司 作为代谢调节剂的芳基和杂芳基衍生物及其所涉及的疾病如糖尿病和高血糖症的预防和治疗
AR045047A1 (es) 2003-07-11 2005-10-12 Arena Pharm Inc Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
RU2404968C2 (ru) 2005-04-08 2010-11-27 Дайити Санкио Компани, Лимитед Пиридилдиметилсульфоновое производное
JP5198877B2 (ja) * 2006-01-31 2013-05-15 株式会社エーピーアイ コーポレーション ベンゾアゼピノン類の製造方法
TW200920362A (en) 2007-09-11 2009-05-16 Daiichi Sankyo Co Ltd Alkylsulfone derivatives
FR2932800B1 (fr) * 2008-06-20 2015-02-20 Servier Lab Nouveau procede de synthese de la 7,8-dimethoxy-1,3-dihydro- 2h-3-benzazepin-2-one, et application a la synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable
EA201390421A1 (ru) 2010-09-22 2013-09-30 Арена Фармасьютикалз, Инк. Модуляторы рецептора gpr119 и лечение связанных с ним нарушений
KR101899014B1 (ko) 2012-01-06 2018-09-17 삼성전자주식회사 비엘디씨 모터의 제어 장치 및 그 방법
CN102690231B (zh) * 2012-04-11 2014-07-09 南京友杰医药科技有限公司 治疗阿尔茨海默病潜在药物司马西特的合成方法
WO2014171434A1 (ja) 2013-04-19 2014-10-23 国立大学法人岡山大学 アミロイドβ蛋白質により誘発される認知障害の治療剤およびアルツハイマー病治療薬、ならびにこれらに関連する治療方法および病態解析方法
EP4445956A3 (en) 2015-01-06 2024-12-04 Arena Pharmaceuticals, Inc. Compound for use in treating conditions related to the s1p1 receptor
PL3310760T3 (pl) 2015-06-22 2023-03-06 Arena Pharmaceuticals, Inc. Krystaliczna sól L-argininy kwasu (R)-2-(7-(4-cyklopentylo-3-(trifluorometylo)benzyloksy)- 1,2,3,4-tetrahydrocyklo-penta[b]indol-3-ilo)octowego do zastosowania w zaburzeniach związanych z receptorem S1P1
CN110520124A (zh) 2017-02-16 2019-11-29 艾尼纳制药公司 用于治疗原发性胆汁性胆管炎的化合物和方法
CA3102136A1 (en) 2018-06-06 2019-12-12 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the s1p1 receptor
IL296723A (en) 2020-03-26 2022-11-01 Seagen Inc Methods of treating multiple myeloma

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP970705A2 (en) * 1996-12-23 1998-10-31 Warren J. Porter CYCLOALKYL, LACTAM, LACTONE AND RELATED COMPOUNDS, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, AND METHODS FOR INHIBITING "beta" -AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS BY USE OF SUCH COMPOUNDS
CA2324474A1 (en) * 1998-06-22 1999-12-29 Elan Pharmaceuticals, Inc. Compounds for inhibiting beta-amyloid peptide release and/or its synthesis
WO2001034571A1 (en) * 1999-11-09 2001-05-17 Eli Lilly And Company β-AMINOACID COMPOUNDS USEFUL FOR INHIBITING β-AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS

Also Published As

Publication number Publication date
PT1353910E (pt) 2007-08-20
UA77165C2 (en) 2006-11-15
EP1353910B1 (en) 2007-05-23
DK1353910T3 (da) 2007-09-10
JP4116431B2 (ja) 2008-07-09
HRP20030385A2 (en) 2003-08-31
ZA200303411B (en) 2004-08-02
PE20020798A1 (es) 2002-09-06
ES2286162T3 (es) 2007-12-01
PL211018B1 (pl) 2012-03-30
ATE362919T1 (de) 2007-06-15
BR0115424A (pt) 2003-10-21
JP2004521084A (ja) 2004-07-15
AU2002224321B2 (en) 2006-10-19
CA2425497C (en) 2010-08-17
KR20030045194A (ko) 2003-06-09
CN1575282A (zh) 2005-02-02
EP1353910A2 (en) 2003-10-22
MY141607A (en) 2010-05-31
SV2003000741A (es) 2003-01-13
EA200300579A1 (ru) 2003-12-25
CN101624372A (zh) 2010-01-13
SK287794B6 (sk) 2011-10-04
WO2002040451A2 (en) 2002-05-23
ECSP034598A (es) 2003-06-25
SK5432003A3 (en) 2004-09-08
MXPA03004250A (es) 2003-09-22
AU2432102A (en) 2002-05-27
IL155275A0 (en) 2003-11-23
TWI235151B (en) 2005-07-01
CZ20031340A3 (cs) 2004-06-16
DE60128587D1 (de) 2007-07-05
CA2425497A1 (en) 2002-05-23
HUP0301862A2 (hu) 2003-09-29
EA006919B1 (ru) 2006-04-28
NO20032215L (no) 2003-07-16
PL360991A1 (en) 2004-09-20
NO325217B1 (no) 2008-02-25
DE60128587T2 (de) 2008-01-31
CY1106682T1 (el) 2012-05-23
HUP0301862A3 (en) 2007-09-28
US20040248878A1 (en) 2004-12-09
CN100516047C (zh) 2009-07-22
DZ3454A1 (fr) 2002-05-23
NO20032215D0 (no) 2003-05-15
WO2002040451A3 (en) 2003-08-28

Similar Documents

Publication Publication Date Title
AR031356A1 (es) Compuesto lacta mico
CY1106366T1 (el) Ενωση λακταμης για την αναστολη της απελευθερωσης ή της συνθεσης βητα-αμυλοειδους πεπτιδιου
SE0101675D0 (sv) Novel composition
ECSP003682A (es) Compuestos para el tratamiento de la isquemia
DE50005437D1 (en) Substituierte thien-3-yl-sulfonylamino(thio)carbonyl-triazolin(thi)one
PL363168A1 (pl) Cyklopentanole, kompozycje zawierające takie związki i sposoby leczenia
EA200300050A1 (ru) Гликопептидфосфонатные производные
SV2004001485A (es) Composicion de ziprasidona y controles sinteticos ref. pc23201
CY1106132T1 (el) Παραγωγα πιπepιδινης ως αναστολεις καναλιου καλιου
ES2243579T3 (es) Derivados de pirazolopirideno.
MY122829A (en) Linezolid-crystal form ii
NO20043016L (no) 6-aminomorfinan-derivater, fremgangsmate for fremstilling og anvendelse derav
MXPA03009602A (es) Analogos de nociceptina.
MXPA05008960A (es) Oxazolidinonas de indolona antibacteriales, intermedios para su preparacion y composiciones farmaceuticas que las contienen.
DE60100539D1 (en) Tosylprolin-derivate als thymidylat-synthase inhibitoren
DE69827614D1 (de) Chinoxalindionen
YU26001A (sh) Derivati ureidopiperidina kao selektivni antagonisti ljudskih nk3 receptora
ATE328595T1 (de) Carvedilolpolymorph
ATE364619T1 (de) Tibolonformulierungen
BR0113202A (pt) Compostos de trioxepano
AR021343A1 (es) Nuevos acetales derivados de los 2-alquil-5-halo-3-[2'-(tetrazol-5-il)-bifenil-4-ilmetil]-3h-imidazol-4-carbaldehidos
HN2000000089A (es) Polimorfos de un diclohidrato cristalino de azobiciclo (2,2,2) oct - 3 - ilamina y sus composiciones farmaceuticas.
UY27523A1 (es) Tetra-, penta-, hexa-y heptapéptidos con actividad antiangiogénica
PT1140932E (pt) Derivados de 1,8-benzonaftiridina
DE60235538D1 (de) Glycopeptid-antibiotika

Legal Events

Date Code Title Description
FA Abandonment or withdrawal